21 – 30 of 151
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Plasma phosphorylated tau 217 in preclinical Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Plasma p-tau181 and p-tau217 in discriminating PART, AD and other key neuropathologies in older adults
(
- Contribution to journal › Article
-
Mark
Discriminative accuracy of the A/T/N scheme to identify cognitive impairment due to Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Clinical performance and robustness evaluation of plasma amyloid-β42/40 prescreening
(
- Contribution to journal › Article
-
Mark
Screening over Speech in Unselected Populations for Clinical Trials in AD (PROSPECT-AD) : Study Design and Protocol
(
- Contribution to journal › Article
-
Mark
Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment patients : A multi-cohort study
(
- Contribution to journal › Article
-
Mark
Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients
(
- Contribution to journal › Article
-
Mark
Test-retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models
(
- Contribution to journal › Article
-
Mark
Gray matter hypoperfusion is a late pathological event in the course of Alzheimer's disease
2023) In Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 43(4). p.565-580(
- Contribution to journal › Article